Companies Forge Ahead
PRC Awaits U.S./EU/WHO Biosimilars Guidance
By Cornelia Zou
Monday, October 21, 2013
HONG KONG – Defying all expectations of an early announcement, biosimilar developers in China are unlikely to see any kind of regulatory framework in the near future. With approximately 60 biosimilars already available in China despite the regulatory lag, that market is estimated to be worth close to $2 billion by 2015.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.